Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies
Authors:
- 30 August 2022
- journal article
- review article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 46 (2) , 213-234
Abstract
Purpose Neuroendocrine neoplasms can occur as part of inherited disorders, usually in the form of well-differentiated, slow-growing tumors (NET). The main predisposing syndromes include: multiple endocrine neoplasias type 1 (MEN1), associated with a large spectrum of gastroenteropancreatic and thoracic NETs, and type 4 (MEN4), associated with a wide tumour spectrum similar to that of MEN1; von Hippel-Lindau syndrome (VHL), tuberous sclerosis (TSC), and neurofibromatosis 1 (NF-1), associated with pancreatic NETs. In the present review, we propose a reappraisal of the genetic basis and clinical features of gastroenteropancreatic and thoracic NETs in the setting of inherited syndromes with a special focus on molecularly targeted therapies for these lesions. Methods Literature search was systematically performed through online databases, including MEDLINE (via PubMed), and Scopus using multiple keywords’ combinations up to June 2022. Results Somatostatin analogues (SSAs) remain the mainstay of systemic treatment for NETs, and radiolabelled SSAs can be used for peptide-receptor radionuclide therapy for somatostatin receptor (SSTR)-positive NETs. Apart of these SSTR-targeted therapies, other targeted agents have been approved for NETs: the mTOR inhibitor everolimus for lung, gastroenteropatic and unknown origin NET, and sunitinib, an antiangiogenic tyrosine kinase inhibitor, for pancreatic NET. Novel targeted therapies with other antiangiogenic agents and immunotherapies have been also under evaluation. Conclusions Major advances in the understanding of genetic and epigenetic mechanisms of NET development in the context of inherited endocrine disorders have led to the recognition of molecular targetable alterations, providing a rationale for the implementation of treatments and development of novel targeted therapies.Keywords
This publication has 162 references indexed in Scilit:
- Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)Molecular and Cellular Endocrinology, 2014
- Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2Journal of Oncology, 2012
- 68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor–Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine TumorsJournal of Nuclear Medicine, 2010
- von Hippel-Lindau disease: treatment of retinal haemangioblastomas by targeted therapy with systemic bevacizumabActa Ophthalmologica, 2009
- O 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine TumorsClinical Cancer Research, 2008
- Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversiesCancer, 2008
- Surgery on neuroendocrine tumoursBest Practice & Research Clinical Endocrinology & Metabolism, 2007
- Association neurofibromatose de type I, phéochromocytome et somatostatinome de l'ampoule de Vater. Revue de la littératureAnnales de Chirurgie, 2006
- Multiple Neuroendocrine Tumors of the Pancreas in von Hippel-Lindau Disease PatientsThe American Journal of Pathology, 1998
- Association of Parathyroid Tumors in Multiple Endocrine Neoplasia Type 1 with Loss of Alleles on Chromosome 11New England Journal of Medicine, 1989